Evaluation of ProC Global assay in women with a history of venous thromboembolism on hormonal therapy

Summary

The risk of thrombosis in women increases significantly during treatment with hormonal therapy (HT). The aim of this study was to evaluate ProC Global assay in women with a history of venous thromboembolism (VTE) while using HT. Protein C activation time normalized ratio (PCAT-NR) levels were significantly lower in 32 women with a history ofVTE while using HT (0.72 ± 0.1) compared with 56 healthy controls without HT, matched by age at blood sampling (0.99 ± 0.2) and 40 healthy controls with HT, matched by age and HT at VTE event (0.94 ± 0.2) (P<0.001 for both). PCAT-NR lower than the cut-off level of 0.8 was found in 23/32 (72%) patients compared with 5/56 (9%) age-matched controls (OR=26, 95%CI: 7-106, P<0.001) and 9/40 (22.5%) of HT-matched controls (OR=9, 95%CI: 2.7-30, P<0.001). Any thrombophilic risk factor was found in 20/32 (62.5%) of patients compared with 12/56 (21.4%) of agematched controls (OR=6, 95%CI: 2.1-10, P<0.001) and 12/40 (30%) of HT-matched controls (OR=4, 95%CI: 1.3-11.8, P=0.006).Out of the variables that are risk factors of VTE as age, HT or thrombophilic risk factor, ProC Global assay was found in the multivariate analysis - logistic regression, as the parameter that was the most associated with patient group [Exp(B)=15.8, 95% CI: 4.2-59.0, P<0.001]. In conclusion, abnormal PCAT-NR is associated with VTE in women using HT. ProC Global assay may potentially serve asa diagnostic tool for evaluating the risk of VTE in women prior to administration of HT.

Keywords

Thrombophilic risk factor - oral contraceptive - hormonal therapy - ProC Global assay

• References

• 1 Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral Contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86: 112-23.
• 2 Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 201-10.
• 3 Walker ID. Hormone replacement therapy and venous thromboembolism. Thromb Res 2005; 115 (Suppl. 01) 88-92.
• 4 Vandenbroucke JP, Koster T, Briët E. et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
• 5 Rosendaal FR, Koster T, Vandenbroucke JP. et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated proteinC resistance). Blood 1995; 85: 1504-8.
• 6 Simioni P, Sanson BJ, Prandoni P. et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
• 7 Olivieri O, Friso S, Manzato F. et al. Resistance to activated protein C in healthy women taking oral contraceptives. BrJ Haematol 1995; 91: 465-70.
• 8 Henkens CM, Bom VJ, Seinen AJ. et al. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
• 9 Rosing J. Mechanisms of OC related thrombosis. Thromb Res 2005; 115 (Suppl. 01) 81-3.
• 10 de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated proteinC in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
• 11 Kraus M, Noah M, Fickenscher K. The PCAT--a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995; 79: 217-22.
• 12 Robert A, Eschwege V, Hameg H. et al. Anticoagulant response to Agkistrodon contortrix venom (ACV test):a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996; 75: 562-6.
• 13 Dati F, Hafner G, Erbes H. et al. ProC Global: the first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43: 1719-23.
• 14 Tripodi A, Akhavan S, Asti D. et al. Laboratory screening of thrombophilia Evaluation of the diagnostic efficacy ofa global test to detect congenital deficiencies of the proteinC anticoagulant pathway. Blood Coag Fibrinol 1998; 09: 485-9.
• 15 Toulon P, Halbmeyer WM, Hafner G. et al. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay Results of European multicenter evaluation. Blood Coag Fibrinol 2000; 11: 447-54.
• 16 Grand’Maison A, Bates SM, Johnston M. et al. ‘ProC Global’: a functional screening test that predicts recurrent venous thromboembolism. Thromb Haemost 2005; 93: 600-4.
• 17 Sarig G, Lanir N, Hoffman R. et al. ProteinC global assay in the evaluation of women with idiopathic pregnancy loss. Thromb Haemost 2002; 87: 32-6.
• 18 Heilmann L, von Tempelhoff GF, Pollow K. Pro C Global assay in the evaluation of women with history of severe pre-eclampsia or HELLP syndrome. Clin Appl Thromb Hemost 2002; 08: 319-24.
• 19 Sarig G, Younis JS, Hoffman R. et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77: 342-7.
• 20 Toulon P, Adda R, Perez P. Sensitivity of the ProC Global assay for protein C pathway abnormalities Clinical experience in 899 unselected patients with venous thromboembolism. Thromb Res 2001; 104: 93-103.
• 21 Wu O, Robertson L, Langhorne P. et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17-25.
• 22 Gemmati D, Serino ML, Tognazzo S. et al. The reduced sensitivity of the ProC? Global test in proteins deficient subjects reflectsa reduction in the associated thrombotic risk. Blood Coag Fibrinol 2001; 12: 691-7.
• 23 Rosing J, Tans G, Nicolaes GA. et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using secondand third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
• 24 Wu O, Robertson L, Twaddle S. et al. TheThrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131: 80-90.